Market Overview

Insys Therapeutics: The Brotherhood of Thieves?

Related INSY
Big Pharma Is Fighting Legalized Marijuana Any Way It Can
Mid-Day Market Update: Insteel Industries Drops Following Q4 Results; DragonWave Shares Spike Higher
Medical Marijuana Offers Opportunities For The Daring Investor (Seeking Alpha)

Roddy Boyd, the journalist behind the Valeant Pharmaceuticals Intl (NYSE: VRX) specialty pharmacy controversy months ago, has released a new report on Insys Therapeutics Inc (NASDAQ: INSY).

Boyd's piece titled "The Brotherhood of Thieves" highlights how Insys was able to double the insurance approval rates of Subsys, over competitors that were much more established.

Continuing his initial report on the company in December, Boyd followed up saying, "executives continued to pressure employees to develop new ways to mislead insurance companies into granting coverage to patients prescribed its drug Subsys."

Related Link: Depomed Validates Horizon Pharma Rejection Offer

In his report, Boyd obtained audio recording of a meeting held in November that shows (according to Boyd) executive Jeff Kobos admitting to the unit's dishonesty. Boyd also highlights, "conversational gambits" to deflect pharmacy benefit manager worker questions with.

In reponse to the report, Insys Therapeutics released a statement rejecting the commentary. "Insys rejects the recent media reports' account of the Company's practices as misleading and unreliable, especially in light of the biased agenda held by the individuals who made these misrepresentations," the company wrote.

Shares of Insys Therapeutics remain volatile off the open, trading down 3.47 percent at $21.78.

Latest Ratings for INSY

Oct 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy
Apr 2016Janney CapitalInitiates Coverage onBuy

View More Analyst Ratings for INSY
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Short Ideas Analyst Ratings Movers Media Trading Ideas


Related Articles (VRX + INSY)

View Comments and Join the Discussion!